Schizophrenia Clinical Trial
Official title:
An Open-label Study to Determine the Pharmacokinetics, Safety and Tolerability of Single Ascending Doses of a Subcutaneous Injection of Lumateperone Long-Acting Injectable (LAI) Formulation in Patients With Schizophrenia
Verified date | December 2022 |
Source | Intra-Cellular Therapies, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label study to determine the pharmacokinetics, safety and tolerability of single ascending doses of lumateperone long-acting injectable formulation in patients with schizophrenia. Patients will be enrolled in one of up to four cohorts. All patients will receive oral lumateperone for 5 days, followed by a 5-day washout of oral lumateperone, then followed by a single dose of lumateperone LAI.
Status | Completed |
Enrollment | 37 |
Est. completion date | May 23, 2022 |
Est. primary completion date | May 23, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Key Inclusion Criteria: - Male or female patients aged 18 to 50 years, inclusive - Clinical diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) - Clinically stable and free from acute exacerbation of psychosis for at least 3 months prior to Screening per Investigator assessment - On a stable dose of antipsychotic medication, including lumateperone, for at least 3 months prior to the Screening Visit - Clinical Global Impression - Severity (CGI-S) score = 3 Key Exclusion Criteria: - Clinically significant abnormality within 2 years of Screening that, in the Investigator's opinion, may place the patient at risk or interfere with study outcome variables - History of psychiatric condition other than schizophrenia that, in the Investigator's opinion, may be detrimental to participation in the study - Any suicidal ideation within the 6 months prior to Screening, any suicidal behavior within 2 years prior to Screening based on the Columbia-Suicide Severity Rating Scale (C-SSRS) (excluding self-injurious, non-suicidal behavior), and/or Investigator assessment that the patient is a safety risk to him/herself or others - Surgical or medical condition (active or chronic) that in the Investigator's opinion may interfere with drug absorption, distribution, metabolism, or excretion of the study drug or any other condition that may place the patient at risk; history of gastric bypass or sleeve gastrectomy; history of severe dystonic reaction on antipsychotics such as laryngeal spasm |
Country | Name | City | State |
---|---|---|---|
United States | Clinical Site | Long Beach | California |
United States | Clinical Site | Marlton | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Intra-Cellular Therapies, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pharmacokinetics: Maximum observed plasma concentration (Cmax) of lumateperone and metabolites | predose and at multiple timepoints up to 7 weeks postdose | ||
Primary | Pharmacokinetics: Time of maximum observed plasma concentration (Tmax) of lumateperone and metabolites | predose and at multiple timepoints up to 7 weeks postdose | ||
Primary | Pharmacokinetics: Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of lumateperone and metabolites | predose and at multiple timepoints up to 7 weeks postdose | ||
Primary | Pharmacokinetics: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf) of lumateperone and metabolites | predose and at multiple timepoints up to 7 weeks postdose | ||
Primary | Pharmacokinetics: Terminal elimination half-life (T1/2) of lumateperone and metabolites | predose and at multiple timepoints up to 7 weeks postdose | ||
Primary | Pharmacokinetics: Maximum observed plasma concentration (Cmax,BR) of lumateperone and metabolites during burst-release phase | predose and at multiple timepoints up to 7 weeks postdose | ||
Primary | Pharmacokinetics: Time of maximum observed plasma concentration (Tmax,BR) of lumateperone and metabolites during burst-release phase | predose and at multiple timepoints up to 7 weeks postdose | ||
Primary | Pharmacokinetics: Area under the plasma concentration-time curve (AUC0-t,BR) of lumateperone and metabolites during burst-release phase | predose and at multiple timepoints up to 7 weeks postdose | ||
Primary | Pharmacokinetics: Maximum observed plasma concentration (Cmax,SR) of lumateperone and metabolites during sustained-release phase | predose and at multiple timepoints up to 7 weeks postdose | ||
Primary | Pharmacokinetics: Time of maximum observed plasma concentration (Tmax,SR) of lumateperone and metabolites during sustained-release phase | predose and at multiple timepoints up to 7 weeks postdose | ||
Primary | Pharmacokinetics: Area under the plasma concentration-time curve (AUC0-t,SR) of lumateperone and metabolites during sustained-release phase | predose and at multiple timepoints up to 7 weeks postdose | ||
Secondary | Percentage of participants with treatment-emergent AEs | up to 7 weeks postdose | ||
Secondary | Change from baseline in Systolic and Diastolic Blood Pressure | up to 7 weeks postdose | ||
Secondary | Change from baseline in hemoglobin | up to 7 weeks postdose | ||
Secondary | Change from baseline in platelet count | up to 7 weeks postdose | ||
Secondary | Change from baseline in white blood cell count | up to 7 weeks postdose | ||
Secondary | Change from baseline in aspartate aminotransferase | up to 7 weeks postdose | ||
Secondary | Change from baseline in alanine aminotransferase | up to 7 weeks postdose | ||
Secondary | Change from baseline in glucose | up to 7 weeks postdose | ||
Secondary | Change from baseline in creatine kinase | up to 7 weeks postdose | ||
Secondary | Change from baseline in ECG QT Interval | up to 7 weeks postdose | ||
Secondary | Change from baseline in Abnormal Involuntary Movement Scale | AIMS is a measure of facial and oral movements, extremity movements and trunk movements. Items are rated on a scale from none (0) to severe (4). | up to 7 weeks postdose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |